Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting....

Full description

Saved in:
Bibliographic Details
Published in:Drug design, development and therapy development and therapy, 2017-01, Vol.11, p.2399-2408
Main Authors: Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María Del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José
Format: Article
Language:English
Subjects:
Analysis
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Care and treatment
Clinical trials
Cytogenetics
Dexamethasone
Dexamethasone - administration & dosage
Disease
Dosage and administration
Drug Design
Drug dosages
Drug therapy
Evidence-based medicine
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Immunomodulation
Medical prognosis
Multiple Myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Patients
Pharmacology
Pomalidomide
Proteins
Renal failure
Review
Steroids
Survival Rate
Thalidomide - administration & dosage
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Working groups
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
ISSN:1177-8881
1177-8881
DOI:10.2147/DDDT.S115456